Top in hem/onc: Oncologist serves the underserved; liquid biopsies in cancer care
Click Here to Manage Email Alerts
Nathalie D. Mckenzie, MD, is a gynecologic oncologist and program director of the gynecologic oncology fellowship at AdventHealth Cancer Institute who has spent her career serving patients in countries with limited access to cancer therapies.
Healio spoke with McKenzie about the importance of affordable cancer treatments, her ongoing mission work in Haiti to serve the underserved and her plans for future research efforts. It was the top story in hematology/oncology last week.
Another top story was about the evolution of liquid biopsies in cancer care and how they are assisting clinicians in treatment decisions.
“A lot of people are not aware of how powerful this technology is,” Wafik S. El-Deiry, MD, PhD, FACP, an associate dean for oncologic sciences at Warren Alpert Medical School and director of the Legorreta Cancer Center at Brown University, told Healio. “There's a lot of information in those liquid biopsies, and I think it's important for our colleagues all around the country to learn about the utility of what can be learned to treat specific tumor types.”
Read these and more top stories in hematology/oncology below:
Gynecologic oncologist’s mission is to serve the underserved
Patients in low- to middle-income countries have limited access to some of the most effective targeted cancer therapies, and those in the U.S. with insurance may also encounter challenges as copays and deductibles make certain drugs beyond their grasp. Read more.
Liquid biopsy continues its evolution in guiding cancer care
Often regarded in oncology as a complementary diagnostic or early detection tool, liquid biopsy has moved into routine clinical use to help guide treatment decisions in the era of targeted, molecular-based therapies. Read more.
VIDEO: Bispecifics here to stay for treatment of multiple myeloma
In this video perspective, Nikhil C. Munshi, MD, discusses presentations from the ASH Annual Meeting and Exposition that focus on advances in bispecific antibody treatments for patients with multiple myeloma. Watch video.
Liquid biopsy takes on pancreatic cancer
Pancreatic cancer is among the deadliest malignancies, and those who specialize in its treatment eagerly embrace any tools that may help extend patient survival. Read more.
Prostate cancer 2022: AI-guided therapy and a new standard in high-risk disease
Several novel treatment regimens for prostate cancer emerged during the past year. Read more.